Close the acquisition of the Dunkirk Facility leasehold interest
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Jan 2022
- Due
- 31 Mar 2022
- Delivered
- 14 Feb 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Dunkirk Facility transaction is expected to close in the first quarter of 2022 and is subject to customary closing conditions, including obtaining consent of certain 3rd party organizations and a lender of Athenex.”
What we found
Evidence strength A What the grades mean
ImmunityBio successfully completed the acquisition of the Dunkirk Facility leasehold interest on February 14, 2022, which falls within the first quarter of 2022.
-
A ImmunityBio, Inc. 10-Q filed 2022-05-10
“On February 14, 2022, we completed the acquisition of a leasehold interest in approximately 409,000 rentable square feet of current Good Manufacturing Practice (cGMP) ISO Class 5 pharmaceutical manufacturing space in western New York (the Dunkirk Facility)” ✓ confirmed on the page
Market reaction: the shares moved -9.1% against the S&P 500 over the three sessions around the disclosure (9 May 2022 to 12 May 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Dunkirk Facility leasehold interest
- Where
- New York
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to customary closing conditions; obtaining consent of certain 3rd party organizations; obtaining consent of a lender of Athenex
- Depends on
- Counterparty, Financing
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-IBRX-002818 · Corrections policy